JP2020511406A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511406A5
JP2020511406A5 JP2019529529A JP2019529529A JP2020511406A5 JP 2020511406 A5 JP2020511406 A5 JP 2020511406A5 JP 2019529529 A JP2019529529 A JP 2019529529A JP 2019529529 A JP2019529529 A JP 2019529529A JP 2020511406 A5 JP2020511406 A5 JP 2020511406A5
Authority
JP
Japan
Prior art keywords
cells
car
microliter
genetically engineered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019529529A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511406A (ja
JP7227131B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/064364 external-priority patent/WO2018102787A1/en
Publication of JP2020511406A publication Critical patent/JP2020511406A/ja
Publication of JP2020511406A5 publication Critical patent/JP2020511406A5/ja
Priority to JP2022034078A priority Critical patent/JP2022084710A/ja
Application granted granted Critical
Publication of JP7227131B2 publication Critical patent/JP7227131B2/ja
Priority to JP2024013333A priority patent/JP2024045372A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019529529A 2016-12-03 2017-12-01 Car-t細胞の投薬を決定するための方法 Active JP7227131B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022034078A JP2022084710A (ja) 2016-12-03 2022-03-07 Car-t細胞の投薬を決定するための方法
JP2024013333A JP2024045372A (ja) 2016-12-03 2024-01-31 Car-t細胞の投薬を決定するための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662429738P 2016-12-03 2016-12-03
US62/429,738 2016-12-03
US201762514765P 2017-06-02 2017-06-02
US62/514,765 2017-06-02
US201762515523P 2017-06-05 2017-06-05
US62/515,523 2017-06-05
PCT/US2017/064364 WO2018102787A1 (en) 2016-12-03 2017-12-01 Methods for determining car-t cells dosing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022034078A Division JP2022084710A (ja) 2016-12-03 2022-03-07 Car-t細胞の投薬を決定するための方法

Publications (3)

Publication Number Publication Date
JP2020511406A JP2020511406A (ja) 2020-04-16
JP2020511406A5 true JP2020511406A5 (enExample) 2021-01-14
JP7227131B2 JP7227131B2 (ja) 2023-02-21

Family

ID=60935955

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019529529A Active JP7227131B2 (ja) 2016-12-03 2017-12-01 Car-t細胞の投薬を決定するための方法
JP2022034078A Withdrawn JP2022084710A (ja) 2016-12-03 2022-03-07 Car-t細胞の投薬を決定するための方法
JP2024013333A Withdrawn JP2024045372A (ja) 2016-12-03 2024-01-31 Car-t細胞の投薬を決定するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022034078A Withdrawn JP2022084710A (ja) 2016-12-03 2022-03-07 Car-t細胞の投薬を決定するための方法
JP2024013333A Withdrawn JP2024045372A (ja) 2016-12-03 2024-01-31 Car-t細胞の投薬を決定するための方法

Country Status (13)

Country Link
US (1) US20200078400A1 (enExample)
EP (2) EP4279136A3 (enExample)
JP (3) JP7227131B2 (enExample)
KR (1) KR20190104528A (enExample)
CN (1) CN110290807B (enExample)
AU (1) AU2017368333A1 (enExample)
BR (1) BR112019011065A2 (enExample)
CA (1) CA3045355A1 (enExample)
ES (1) ES2961666T3 (enExample)
MA (1) MA46963A (enExample)
MX (1) MX2019006286A (enExample)
RU (1) RU2019120398A (enExample)
WO (1) WO2018102787A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3209690B1 (en) 2014-10-20 2021-05-05 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
ES2988795T3 (es) 2017-02-27 2024-11-21 Juno Therapeutics Inc Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular
CA3061945A1 (en) * 2017-05-01 2018-11-08 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
KR102845789B1 (ko) 2017-11-01 2025-08-14 주노 쎄러퓨티크스 인코퍼레이티드 B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
CN111989106A (zh) * 2017-12-01 2020-11-24 朱诺治疗学股份有限公司 基因工程化细胞的给药和调节方法
EP4403224A3 (en) * 2018-06-01 2024-07-31 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
WO2020092475A1 (en) * 2018-10-31 2020-05-07 The Children's Hospital Of Philadelphia T cells from lymphatic fluid for diagnostic and therapeutic use
WO2020097403A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
US12429485B2 (en) 2018-12-14 2025-09-30 The Brigham And Women's Hospital, Inc. Biomarker panels for on-treatment prediction of response to immuno-oncology drugs
CN115397974A (zh) 2020-01-23 2022-11-25 儿童医疗中心有限公司 由人类多能干细胞进行无基质t细胞分化
CN114644716A (zh) * 2022-04-07 2022-06-21 苏州大学 一种抗bxmas1嵌合抗原受体及其修饰的免疫细胞及应用
US20250345432A1 (en) * 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5565566A (en) 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
JPH065637Y2 (ja) 1988-02-12 1994-02-09 コーア株式会社 チップ部品
US5298508A (en) 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5424297A (en) 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
EP0672144A1 (en) 1992-10-20 1995-09-20 Chiron Corporation Interleukin-6 receptor antagonists
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
WO1994025462A1 (en) 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
US5504090A (en) 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5670501A (en) 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
JP4431638B2 (ja) 1996-01-29 2010-03-17 アメリカ合衆国 ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
WO1998006842A1 (en) 1996-08-16 1998-02-19 Schering Corporation Mammalian cell surface antigens; related reagents
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
EP1019439B1 (en) 1997-10-02 2011-11-16 Altor BioScience Corporation Soluble single-chain t-cell receptor proteins
WO1999020758A1 (en) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
CA2319236A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
AU758949B2 (en) 1998-05-19 2003-04-03 Avidex Limited Multivalent T cell receptor complexes
US6326390B1 (en) 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6313131B1 (en) 1999-02-16 2001-11-06 Upsher-Smith Laboratories, Inc. Method of kidney treatment
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
CA2378179A1 (en) 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
US20010053996A1 (en) 2000-01-06 2001-12-20 Atkinson Paul D. System and method for distributing and controlling the output of media in public spaces
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU2001265346A1 (en) 2000-06-02 2001-12-17 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
CA2425862C (en) 2000-11-07 2013-01-22 City Of Hope Cd19-specific redirected immune cells
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
EP1389203B8 (en) 2001-02-27 2010-03-10 The Governement of the United States of America, represented by The Secretary Department of Health and Human services Analogs of thalidomide as angiogenesis inhibitors
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
EP1421115B1 (en) 2001-08-31 2005-03-02 Avidex Limited Soluble t cell receptor
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
EP1465634B1 (en) 2001-12-12 2014-10-22 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Methods for using adenosine receptor inhibitors to enhance immune response and inflammation
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20030223994A1 (en) 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
ME00204B (me) 2002-09-06 2011-02-10 Medarex Llc Terapijsko, humano, monoklonsko anti-il-1r1antitijelo
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
RU2369636C2 (ru) 2003-05-23 2009-10-10 Уайт Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
JP2007518399A (ja) 2003-12-02 2007-07-12 ジェンザイム コーポレイション 肺癌を診断および治療する組成物並びに方法
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
US20060034850A1 (en) 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
CA2678180A1 (en) 2007-02-13 2008-12-04 Northeastern University Methods and compositions for improving immune responses
DK2141997T3 (da) 2007-03-30 2013-02-11 Sloan Kettering Inst Cancer Konstitutiv ekspression af co-stimulatoriske ligander på adoptivt overførte t-lymfocytter
US7615883B2 (en) 2007-06-06 2009-11-10 Meheen H Joe Wind driven venturi turbine
CA2693677C (en) 2007-07-12 2018-02-13 Tolerx, Inc. Combination therapies employing gitr binding molecules
DK2433713T3 (en) 2007-12-07 2017-09-25 Miltenyi Biotec Gmbh CELL PROCESSING SYSTEMS AND PROCEDURES
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
WO2010003118A1 (en) 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
EP4032552B1 (en) 2008-08-26 2023-10-04 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
WO2010030002A1 (ja) 2008-09-12 2010-03-18 国立大学法人三重大学 外来性gitrリガンド発現細胞
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010065959A1 (en) 2008-12-05 2010-06-10 Northeastern University Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy
RU2595409C2 (ru) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
JP5955771B2 (ja) 2009-10-22 2016-07-20 トーマス・ジェファーソン・ユニバーシティThomas Jefferson University 細胞ベースの抗癌組成物ならびに当該物の製造方法および使用方法
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
ES2717629T3 (es) 2009-11-03 2019-06-24 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
SG181952A1 (en) 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
CA3253628A1 (en) 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
SMT201700250T1 (it) * 2010-11-10 2017-07-18 Amgen Res Munich Gmbh Prevenzione di effetti avversi provocati da domini leganti cd3 specifici
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
RU2688185C2 (ru) 2011-03-23 2019-05-21 Фред Хатчинсон Кэнсер Рисерч Сентер Способ и композиции для клеточной иммунотерапии
PH12013502043A1 (en) 2011-04-01 2013-12-16 Memorial Sloan Kettering Cancer Center T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
JP2014514927A (ja) 2011-04-13 2014-06-26 イミュニカム・エイビイ 抗原特異的t細胞の増殖のための方法
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
JP6368243B2 (ja) 2011-11-11 2018-08-08 フレッド ハッチンソン キャンサー リサーチ センター がんのためのサイクリンa1に標的化されたt細胞免疫療法
US20140377240A1 (en) 2012-01-17 2014-12-25 Northeastern University Methods and compositions for expanding immunosuppressive t regulatory cells in vitro and uses thereof
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
US9751928B2 (en) 2012-05-03 2017-09-05 Fred Hutchinson Cancer Research Center Enhanced affinity T cell receptors and methods for making the same
EP2861622A4 (en) 2012-06-15 2016-06-01 Sinomab Bioscience Ltd Anti-idiotypic anti-CD22 antibodies and uses thereof
HRP20250822T1 (hr) 2012-07-13 2025-09-26 The Trustees Of The University Of Pennsylvania UPRAVLJANJE TOKSIČNOŠĆU ZA PROTUTUMORSKO DJELOVANJE CAR-a
KR102264290B1 (ko) 2012-08-20 2021-06-10 프레드 헛친슨 켄서 리서치 센터 세포 면역요법을 위한 방법 및 조성물
CN112458057A (zh) 2012-10-02 2021-03-09 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
US9405601B2 (en) 2012-12-20 2016-08-02 Mitsubishi Electric Corporation In-vehicle apparatus and program
US9393268B2 (en) 2013-03-15 2016-07-19 Thomas Jefferson University Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same
ES3058841T3 (en) 2013-03-15 2026-03-13 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗-cd19嵌合抗原受體治療癌症
WO2014190273A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
BR112016012795A2 (pt) 2013-12-06 2017-08-08 Celgene Corp Métodos para a determinação da eficácia do fármaco para o tratamento de linfoma difuso de grandes células b, mieloma múltiplo e cânceres mieloides
SI3888674T1 (sl) 2014-04-07 2024-08-30 Novartis Ag Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
DK3166968T3 (da) 2014-05-02 2021-12-06 Univ Pennsylvania Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
RU2020117196A (ru) 2014-08-19 2020-10-15 Новартис Аг Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
EP3209690B1 (en) * 2014-10-20 2021-05-05 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
KR102357004B1 (ko) 2014-10-27 2022-01-27 프레드 헛친슨 켄서 리서치 센터 입양 세포 면역요법의 효능을 강화하기 위한 조성물 및 방법
IL253149B2 (en) * 2014-12-29 2023-11-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11747346B2 (en) * 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
MA44486A (fr) * 2016-03-22 2019-01-30 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Procédés d'intervention précoce pour prévenir ou atténuer la toxicité
KR20200054160A (ko) 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법

Similar Documents

Publication Publication Date Title
JP2020511406A5 (enExample)
JP2022084710A5 (enExample)
Sceneay et al. Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer
US12569700B2 (en) Methods of use of ultra-high dose rate radiation and therapeutic agent
Kang et al. Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines
Domchek et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Tang et al. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes
Yuan et al. Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras–mutant lung cancer
Liu et al. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
Cohen et al. B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
Friedman et al. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
Hughes et al. Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer
Haskó et al. A2B adenosine receptors in immunity and inflammation
CN112449602A (zh) 超高剂量率辐射和治疗剂的使用方法
JP2021508317A5 (enExample)
Jia et al. Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
Zhang et al. A prospective investigation of bispecific CD19/22 CAR T cell therapy in patients with relapsed or refractory B cell non-Hodgkin lymphoma
Hickman et al. LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade
Meng et al. The combination of radiotherapy with immunotherapy and potential predictive biomarkers for treatment of non-small cell lung cancer patients
KR20150042784A (ko) Car의 항-종양 활성에 대한 독성 관리
US20220160871A1 (en) Methods for photoimmunotherapy and related biomarkers
Tucker et al. Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model
Ma et al. The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation
Bulgarelli et al. Radiotherapy and high-dose interleukin-2: clinical and immunological results of a proof of principle study in metastatic melanoma and renal cell carcinoma
Wu et al. Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer